The future of precision medicine: towards a more predictive personalized medicine

Author:

Elemento Olivier1ORCID

Affiliation:

1. Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, U.S.A

Abstract

Precision medicine can be defined as personalized medicine enhanced by technology. In the past, medicine has, in some cases, been personalized. For example, some drugs are dosed on an individualized basis based on age, body-mass index, comorbidities and other clinical parameters. However, overall, medicine has largely followed the ‘one-size-fits-all' paradigm as exemplified in the treatment of essential hypertension or type 2 diabetes mellitus. What has changed in the past few years is that technologies such as high throughput sequencing, mass spectrometry, microfluidics, and imaging can help conduct a multitude of complex measurements on clinical samples. Aided by analytics, these technologies have been providing an increasingly detailed picture of molecular and cellular alterations underlying numerous diseases and have revealed tremendous variability between individuals and patients at the molecular and cellular level. These findings have motivated a more personalized or ‘precision' approach to medicine, in which molecular and cellular markers help tailor patient management to each individual. Here we provide an overview of the key factors driving adoption of precision medicine and highlight current research that may soon make precision medicine more predictive.

Publisher

Portland Press Ltd.

Subject

General Agricultural and Biological Sciences,General Biochemistry, Genetics and Molecular Biology

Reference26 articles.

1. <https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling> (2020)

2. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade;Science,2017

3. <https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors> (2020)

4. Efficacy of larotrectinib in TRK fusion-Positive cancers in adults and children;N. Engl. J. Med.,2018

5. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations;Nat. Genet.,2018

Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3